Skip to content

Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds

Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01790763
Enrollment
0
Registered
2013-02-13
Start date
2015-04-30
Completion date
2015-04-30
Last updated
2015-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Burn Degree Second

Keywords

Burn, Second-degree

Brief summary

The purpose of this study is to determine the extent to which Keramatrix dressing promotes the healing of second-degree burn wounds in pediatric patients.

Detailed description

Efficacy in promoting wound healing will be determined through comparison to Mepilex, an established burn wound dressing.

Interventions

DEVICEKeramatrix

Dressing for second degree burn

DEVICEMepilex

Dressing for second degree wound

Sponsors

Keraplast Technologies, LLC
CollaboratorUNKNOWN
Shriners Hospitals for Children
CollaboratorOTHER
The University of Texas Medical Branch, Galveston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Days to 18 Years
Healthy volunteers
No

Inclusion criteria

patient age 0-18 years old Flame or scald burn 10-30% total body surface area burned Partial-thickness second-degree burns Admission within 72 hours of burn injury Clean non-infected wound as diagnosed by the attending physician

Exclusion criteria

* Patient older than 18 * Causes other than flame or scald injuries (ie.chemical or frostbite) * Wounds noted to be contaminated or infected * Patients who have received previous treatment efforts (topical dressings or previous wound debridement) * Pregnancy lactation * Co-morbidity which may compromise healing: known history of AIDS, ARC, HIV, cancer, autoimmune diseases,cirrhosis, tuberculosis, chronic glucocorticoid therapy, diabetes mellitus, renal insufficiency, hepatic disease, congestive heart failure prior to burn injury, associated severe head injury requiring specific treatment * known allergy to sheep's wool

Design outcomes

Primary

MeasureTime frameDescription
Wound HealingDuration of hospital stay, an expected average of 0.75 days per every percent burn until wound healsWound healing will be determined by measuring wound surface area. Wound surface area will be determined through planimetry, which will be performed on digital photographs of the wounds.

Secondary

MeasureTime frameDescription
Infection ratesDuration of hospital stay, an expected average of 0.75 days per percent burn until wound healsSubjects will be monitored for unusual occurences, including signs and symptoms of infection.
Scarring52 weeks up to 78 weeksScarring will be evaluated using the Vancouver Clinical Scar Scale. Assessments of graft pigmentation, vascularity, pliability and height will be performed at follow-up visits.
Painduration of hospital stay, an expected average of 0.75 days per every percent burn until wound heals, up to 3 times a week during dressing changesPain will be assessed using pain scales according to age.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026